Xencor XNCR 深 沪
等待开盘 08-27 09:30:00 美东时间
29.08
-0.220
-0.75%
华盛通- 最 高29.23
- 今 开28.95
- 成交量 116.45万股
- 最 低 28.54
- 昨 收 29.30
- 总市值 21.62亿
- 52周最高 30.61
- 市盈率 静 --
- 换手率 1.57%
- 52周最低 8.19
- 委 比 -46.34%
- 总股本 7435.34万
- 历史最高 58.345
- 量 比 0.98
- 振 幅 2.35%
- 历史最低 5.75
- 每 手 1
- 风险率 3.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Wedbush Maintains Outperform on Xencor, Raises Price Target to $30
Wedbush analyst David Nierengarten maintains Xencor (NASDAQ:XNCR) with a Outperform and raises the price target from $26 to $30.
08-06 23:43
Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch
Xencor Inc. ($XNCR) announced an update on their ongoing clinical study. Xencor...
08-04 00:32
AstraZeneca, Bristol Myers held merger talks, Financial Times reports
AstraZeneca (AZN) and Bristol Myers Squibb (BMY) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a r...
08-03 03:23
美股大行评级 | 绩后重锤！Meta惨遭16家大行下调目标价；高通、Arm、泛林集团、波士顿科学也遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持TOMI Environmental Solutions"买入"评级，目标价从3.5美元升至7美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从107美元升至114美元
07-31 11:43
Xencor rises after resolving royalty dispute with AstraZeneca
Xencor (XNCR) shares climbed on Thursday after the company settled a royalty dispute with Alexion Pharma related to Ultomiris, a rare disease therapy it markets in partnership with the AstraZeneca (AZ...
07-31 01:03
Wedbush Reiterates Outperform on Xencor, Maintains $26 Price Target
Wedbush analyst David Nierengarten reiterates Xencor (NASDAQ:XNCR) with a Outperform and maintains $26 price target.
07-30 21:39
Xencor Secures Ultomiris Royalty Settlement Payment
Xencor ( ($XNCR) ) just unveiled an announcement. On July 29, 2026, Xencor ente...
07-30 04:38
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Dr. Debra Jeske Zack, a seasoned immunologist with over 25 years of experience, has been appointed as Spero Therapeutics' Chief Medical Officer. Her expertise will strengthen the company's clinical leadership as it advances SP001, a Phase 2-ready third-generation anti-CD40L antibody targeting IgG4-related disease and other immune-mediated conditions. Dr. Zack's leadership is expected to accelerate the development of innovative therapies for patie...
07-27 12:00
